NTLA Stock — Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. (NTLA)

Updated October 16, 2026.

NTLA is a Stock. Total return is -48.3% over the past 10.4 years, 387.2 points behind SPY at 338.9%.

Intellia Therapeutics is a clinical-stage genome editing company developing potentially curative therapeutics based on CRISPR/Cas9 technology for diseases including transthyretin amyloidosis, hereditary angioedema, and various immuno-oncology and autoimmune conditions, with partnerships extending to CAR-T cell and NK cell therapies. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage biotechnology and genome editing innovation, with an understanding that clinical-stage companies typically do not generate current income and carry substantial development and regulatory risks.

NTLA performance versus SPY

Price and return data through 2026-10-16.

Total return is -48.3% over the past 10.4 years, 387.2 points behind SPY at 338.9%. Over the past year its total return — price change plus distributions reinvested — is -54.1%. Its deepest 1-year drawdown was 71.3%.

NTLA key facts

Asset type

Stock

Asset class

Equity

Inception date

05/06/2016

Distribution frequency

None

Last close

$11.42 (as of 2026-10-16)

Market cap

$1,600,246,834

Average volume

8219716.0

Beta

1.801

Payout ratio

0.0%

EPS

$-3.22

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NTLA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 71.3%.

Who may consider NTLA — and who may not

It is a weaker fit for investors who need monthly cash flow (NTLA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NTLA

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions